Skip to content
ESPT
MARKETS / BALCAO / Health care / Pharmaceuticals / PVCT
BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Provectus Biopharmaceuticals, Inc. PVCT

19 fiscal years on record · USD · FY2025 reported · SEC filings only
$336,108
▼ 45.5% YoY
$-5.4M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Our drug product candidates are based on bioactive, synthetic, small molecule rose bengal sodium (“RBS”), which is a member of a class of molecules called halogenated xanthenes (“HXs”). The Company’s proprietary, patented, pharmaceutical-grade RBS is the active pharmaceutical ingredient (“API”) in all our clinical development and non-clinical research programs. The Company is the first entity to advance RBS into clinical trials for the treatment of disease. We hold patents covering RBS and HX medical science. We have six full-time employees who currently serve as CEO, CFO, CTO, president, senior scientist, and controller.

Written from the business description in Provectus Biopharmaceuticals, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 26 March 2026. Every sentence was checked against that document before publication.

Growth

USD 336,108.00
Revenue, FY2025 · full 19-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.3 · Net income -5.4
-10M-20M
2007201020132016201920222025
Compound annual growth
−30.2%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2025 · Operating -1575.3% · Net ·
-500%-1000%-1500%
200720162025
ROE
FY2016 · ROE -246.9%
-200%-400%
200720162025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.
Return on capital employedNot applicable: capital employed was zero or negative in this period, so return on capital employed has no meaning.
Gross margin·
Operating margin-1575.3%
Net margin·
EBITDAUSD -5.3M

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2017 · FCF -10.4
-10M-20M
200720162025
Dividends paid·
Net buybacks·
Share of profit·
Consecutive raises·

Total assetsUSD 697,502.00
EquityUSD -6.3M
CashUSD 251,291.00
Gross debtUSD 241,393.00
Net debtUSD -9,898.00
Current ratio0.08×

Equity was zero or negative — liabilities equaled or exceeded assets. No ratio is shown.

The 19-year record

19 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
PVCT, 19-year financial record
Metric 2025202420232022202120202019201820172016201520142013201220112010200920082007
Revenue $B0.00.00.00.0◌◌◌◌◌◌0.00.00.00.00.0◌◌◌◌
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌
Income tax $B◌◌◌◌◌◌◌◌◌0.00.00.00.00.0◌◌◌◌◌
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B◌◌◌◌◌◌◌◌−0.0◌−0.0−0.0−0.0−0.0−0.0◌−0.0◌◌
EPS, diluted $−0.01−0.01−0.01−0.01−0.01−0.02−0.02−0.02−0.04−0.12−0.13−0.06−0.22−0.11◌◌◌◌◌
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————————————————
ROE %—————————−246.9−118.1−64.4−502.6−174.4−187.6−184.5−126.6−82.5−67.5
Shares out B0.420.420.420.420.420.400.390.380.370.360.200.180.160.120.110.09◌◌◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

MCK · COR · CAH · JNJ · HCA · LLY
Provenance

Company facts, as filed

How we verify · 0 failures in 66 reconciliationsAUDITED

Reconciled in 19 of the 19 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Five checks were skipped: EPS is not tagged before 2012. Four checks were skipped: revenue is not tagged before 2011.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2007

Share this section

Download image